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End-stage renal diseaseAbstract Purpose: To describe our experience with the technique of transhepatic venous access
for hemodialysis and to evaluate its functionality and complications.
Patients and methods: From March 2012 till October 2012, 23 patients with age ranging from 12 to
71 years old having end-stage renal disease (ESRD) were included in our study and were subjected
to transhepatic venous catheter insertion. In 21 patients there were not any remaining patent
peripheral venous accesses. In 2 patients there were only a last one venous access needed to be pre-
served. Thus, it was decided to make THVA. In all the 23 patients the indication was palliative due
to inoperability which was because of inability to insert an arterio-venous graft or making another
arterio-venous ﬁstula. Complications were evaluated and calculated in terms of number of proce-
dures, infection, dislodgement and outcome; in terms of disfunctionality of the catheter.
Follow-up was performed by monitoring the catheter dialysis rate in each session, abdominal ultra-
sonography, ﬂuoroscopy or CT. Mean survival time and median survival time from the start of
treatment were calculated using Kaplan–Meier method.
Results: Twenty-three patients required a single transhepatic access procedure. Because of catheter
dislodgment, two patients required a second access placement procedure, which resulted in a total of
25 separate transhepatic access sites in 23 patients. Technical success was achieved in 22 procedures.
Functionality success was achieved in 20 patients. Functionality failure occurred in 3 patients.
The trans-hepatic catheters stayed in place between 90 and 300 days. Complications occurred in 14
patients.
Conclusion: Based on our ﬁndings, transhepatic hemodialysis catheters have proven to achieve good
long-term functionality. A high level of maintenance is required to preserve patency, although this
approachprovides remarkablydurable access for patientswhohaveotherwise exhausted access options.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Many patients who undergo hemodialysis and have sustained
multiple failed attempts to obtain vascular access, it is often
difﬁcult to achieve access to the central venous system, and
success in achieving such access is often life-saving (1).
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highly effective means of administering temporary venous ac-
cess for dialysis for periods longer than 3 weeks (2).
They are also effective for those who have exhausted other
possibilities, such as arteriovenous ﬁstulas or grafts (3). Tun-
neled transhepatic catheters have become a moderate-term to
long-term mode of dialysis in some patients who have ex-
hausted traditional access sites because of widespread central
venous occlusions, including the femoral veins, collateral neck
veins, and renal veins, through previous catheter placements
and surgeries. As a result, alternative sites have begun to be ex-
plored in patients who have become catheter-dependent,
including translumbar and transhepatic approaches to the infe-
rior vena cava (IVC) (4).
Transhepatic venous access for dialysis was described by Po
et al. in a case report in 1994 (5). Although considered a viable
approach, the transhepatic dialysis catheter is believed to carry
substantial risks, including bleeding, thrombotic occlusion,
infection, hepatic dysfunction, and dislodgment (6).
The aim of this work is to describe our experience with the
technique of transhepatic venous access for hemodialysis and
to evaluate its functionality and complications.Table 1 Patients’ age and causes of ESRD.
Patient Age Cause(s) of ESRD
1 64 SLE
2 61 Aspirin
3 37 Auto-immunity
4 71 Obstructive nephropathy & cancer bladder
5 29 SLE
6 61 Single kidney with obstructive nephropathy
7 39 Auto-immunity
8 43 DM-1
9 69 End stage vascular disease
10 64 DM-1
11 71 HTN & heart problems
12 53 DM, HTN & heart problems (MS)
13 23 Vasculitis & blood disorder
14 46 Vascular disease
15 63 DM-2
16 55 DM, HTN, heart problem & obstr. nephropathy
17 34 DM, refused kidney allograft & auto-immunity
18 25 Stunted growth, DM & vascular disease
19 39 Obstr. uropathy & single rt. kidney
20 49 Polycystic kidney disease
21 57 HTN, DM & bronchogenic carcinoma
22 12 SLE
23 44 SLE2. Patients and methods
From March 2012 till October 2012, 23 patients (3 males, 20
females) with age ranging from 12 to 71 years old (mean age
was 48.4 years old) having end-stage renal disease (ESRD)
were included in our study and were subjected to transhepatic
venous catheter insertion.
All procedures as well as the pre- and post-interventional
assessment and follow-up clinical, radiological & lab. studies
were performed in Vascular & Interventional radiology Unit
and the department of nephrology.
The patients were partly recruited through the interdisci-
plinary Interventional Radiology-Nephrology conference of
the university hospital, in which all cases of ESRD referred
or admitted to our hospital would be discussed by the nephrol-
ogists, surgeons, interventionists, and any other specialists who
happen to be associated with those patients. Cases were mostly
referred to our interventional radiology unit through several
clinics mainly nephrologic.
If, in any of the cases, THVA insertion was justiﬁed, and
the case met the inclusion criteria of our study the possibility
was discussed with the colleagues in the conference to reach
a decision about the line of treatment to be pursued, THVA
insertion or otherwise.
The inclusion criteria of our interventional unit were: Pa-
tients having ESRD on long term hemodialysis and having
no remaining patent peripheral venous access or those who
have only one last venous access needed to be preserved for
permanent access making.
The exclusion criteria were: abnormal bleeding proﬁle, asci-
tes, and allergy to contrast materials.
The causes of ESRD in our patient population were SLE,
hypertension, DM, obstructive nephropathy & others
(Table 1).
In 21 patients there were not any remaining patent periph-
eral venous accesses. In 2 patients there were only a last one
venous access needed to be preserved. Thus, it was decided
to make THVA. In the all 23 patients the indication was pal-liative due to inoperability which was because of inability to
insert an arterio-venous graft or making another arterio-ve-
nous ﬁstula.
The equipment required included:
 A 15-cm 21-gauge needle.
 A 6–9-F coaxial system (Accustick II Introducer System;
Boston Scientiﬁc, Watertown, Mass)
 Guidewire, ‘‘J’’Tip with Straightener, 0.97 mm (0.038
inch.) 50 cm Length.
 Introducer, peel-apart with vessel dilator, 14 Fr.
 Tunneler.
 Hickman hemodialysis/apheresis 13.5-Fr., round dual-
lumen radiopaque silicone catheter, luer lock adapters,
and SureCuff tissue in growth cuff, 2.0 mm lumens,
36 cm overall length, 19 cm tip-to-cuff length (Bard
Access Systems, Salt Lake City, Utah) (Fig. 1) or Ash
Split Cath (Medcomp, Harleyville, Pa) in different
lengths (Fig. 2).
 Injection caps.
 Suture wings.
3. Technique of THV catheter insertion
Twenty-three patients required a single transhepatic access
procedure. Because of catheter dislodgment, two patients re-
quired a second access placement procedure, which resulted
in a total of 25 separate transhepatic access sites in 23 patients.
Eight patients received the Ash Split Cath (Medcomp, Har-
leyville, Pa). One patient received a 28-cm catheter and seven
patients received a 32-cm catheter. Fifteen patients received
the Hickman Hemodialysis/Apheresis 13.5-F round dual lu-
men catheter (Bard Access Systems, Salt Lake City, Utah);
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ceived a 27-cm catheter (Table 2).
Of the 25 catheter placements, 20 tips were positioned in the
right atrium, 4 in the inferior vena cava (two were directed
inferiorly to just above the renal veins, and two succeeded to
be inserted in the proximal cava just below the right atrial
junction), and one in the superior vena cava (Table 3).
All patients underwent routine laboratory studies to evalu-
ate biochemical, hematologic, and coagulation parameters.
Imaging by Doppler was performed on table to determine pa-
tency of the hepatic veins and suprahepatic inferior vena cava.
After informed consent was obtained, all procedures were
performed by using Local anesthesia (subcutaneous Lidocaine
injection BP 2% [TRITTAU: Germany]) administered by ded-
icated interventional radiologist. The right upper lateral
abdominal quadrant was prepared; using real-time ultrasound
guidance (GE, Logic 9 series ultrasound computer system with
3.5 MHz probe) and ﬂuoroscopy set (TOSHIBA, Fenix,
Monoplane, subtraction with ﬂuoroscopy machine), a 15-cm
21-gauge needle was placed through the liver aiming to punc-
ture and cannulate the right or middle hepatic veins and then
directed toward the expected conﬂuence of the hepatic veins
(Fig. 3).
Contrast material (OptirayTM 300 or OmnipaqueTM 350)
was injected though the needle to visualize the hepatic vein.
The needle was repositioned if necessary on the basis of theFig. 1 Hickman catheter, Hemodialysis/Apheresis 13.5-Fr., Rou
Bardaccess.com).
Fig. 2 Split Cath, (Medcomp, Harleyvihepatic venous anatomy, such that it paralleled the course of
either the right or the middle hepatic veins.
Once an acceptable hepatic vein was engaged, a 0.018-inch
(0.46-mm) guide wire (Ultra-Select Nitinol Guidewire; Micro-
vena, White Bear Lake, Minn) was advanced into the right at-
rium. Over this wire, a 6–9-F coaxial system (Accustick II
Introducer System; Boston Scientiﬁc, Watertown, Mass) was
advanced into the hepatic vein to allow placement of the
0.035-inch (0.89-mm) guide wire into the right atrium. Sequen-
tial tract dilation was performed, and a subcutaneous tunnel
was created inferiorly for placement of the dual-lumen dialysis
catheter (Fig. 3).
All catheters were sutured in place. All patients were kept
overnight for observation unless additional hospitalization
was required for medical concerns unrelated to catheter place-
ment or for complications of catheter placement. Catheters
were exchanged because of device failure or bacteremia with-
out tract infection. The time from catheter placement to ex-
change constituted the initial device service interval. With
regard to decreased function, the use of intracatheter thrombo-
lytic agents was included in the calculation of device revision
rates.
Duration of the whole procedure, starting from sterile
draping of the patient and insertion of the catheter till testing
the catheter with contrast injection, ranged between 45 and
90 min, with a mean of 60 min. Only 2 of the procedures lastednd dual-lumen Radiopaque Silicone catheter. (Quoted from
lle, Pa) (Quoted from Medcomp.com).
Table 2 Type and length of catheters used in patients.
Number of patients Type of catheter used
1 28 cm Ash Split Cath
7 32 cm Ash Split Cath
14 36 cm Hickman hemodialysis/apheresis
13.5 F round dual lumen cath
1 27 cm Hickman hemodialysis/Apheresis
13.5 F round dual lumen cath
Table 3 Position of the catheter tip in all procedures.
Number of catheter procedures Position of the catheter tip
20 Right atrium
4 IVC
1 SVC
434 M. El Gharib et al.more than 90 min; 1 of which was complicated by contrast al-
lergy which was managed on the spot with anti-allergic drug
injection. Failure of insertion of the catheter tip inside the
IVC above the level of renal veins led to aborting the proce-
dures in 2 patients.
Complications were evaluated and calculated in terms of
number of procedures, infection, dislodgement and outcome;
in terms of disfunctionality of the catheter.
Follow-up was performed by monitoring the catheter dial-
ysis rate in each session, abdominal ultrasonography, ﬂuoros-
copy or CT.Fig. 3 (A) Needle advanced into the target point of the middle or the
Seldinger-Technique the guidewire is advanced inside the lumen of the
with its dilator is placed over the wire. (D) The subcutaneous tunnel is m
Finally, full catheter insertion & contrast injection to insure good tip4. Statistical analysis
Mean survival time and median survival time from the start of
treatment were calculated using Kaplan–Meier method.
5. Results
5.1. Outcome
5.1.1. Deﬁnitions
All terms speciﬁc to central venous access are outlined in
‘‘Reporting Standards for Central Venous Access’’ as deﬁned
for the Society of Interventional Radiology (SIR) (7).
Tunneled catheter is deﬁned as a central venous catheter
that travels through a subcutaneous tract before entering the
access vein.
Technical success is deﬁned as introduction into the venous
system with the tip positioned in the preferred location and
with adequate catheter function (300 mL/min).
Device failure is deﬁned as any limitation in catheter func-
tion despite a technically successful placement. Device failure
includes thrombosis, migration, inadvertent catheter removal,
kinking, formation of a ﬂow limiting ﬁbrin sheath, infection,
and poor ﬂow. Poor ﬂow is deﬁned as less than 300 mL/min
achieved on the dialyzer, which stems from unknown ori-
gins/not otherwise speciﬁed. Occlusion is deﬁned as any out-
side factor that limits ﬂow during both early and late period.
Fibrin sheath is a type of occlusion composed of ﬁbrin that
can be manifested only during the late period (30 days).right hepatic vein & contrast injected to identify the vein. (B) Using
needle till its distal tip. The needle is then removed. (C) The sheath
ade. (E) The catheter is inserted through the peel away sheath. (F)
position.
Table 4 THVA outcome.
Patient number Minimum Maximum Mean SD
Age (years) 23 12.00 71.00 48.4400 16.33789
Dialysis rate (ml/min) 22 110.00 300.00 267.2727 44.74072
In situ duration (days) 23 0.00 210.00 34.4348 64.22816
Death after (days) 5 14.00 210.00 131.6000 75.59630
Table 5 Patients survival.
30-day mortalities 4%
Procedure-speciﬁc mortalities 0%
1-year survival rate 60.8%
Less than 6 months survival rate 17.3%
Between 6 and 12 m survival rate 8.6%
Fig. 5 Exit site infection.
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ber of catheter-days from initial placement until removal. Sec-
ondary (revised) device service interval is deﬁned as the number
of catheter-days after device replacement using the same access
site.
Total access site interval is deﬁned as the sum total cathe-
ter-days for a single access site (7).
Exit site infection is deﬁned as erythema and induration
within a 2-cm radius from the catheter exit site with no signs
of bacteremia. Bacteremia is deﬁned as having one positive
blood culture without signs and symptoms of infection. Sepsis
is deﬁned as having one positive blood culture with signs and
symptoms of infection. Sepsis not catheter-related is deﬁned as
clinical signs and symptoms of sepsis with negative catheter tip
culture. Catheter-related sepsis is deﬁned as clinical signs and
symptoms of sepsis with positive catheter tip culture (7).
Mean time catheter in situ is deﬁned as the cumulative cath-
eter-days divided by the cumulative number of catheters in the
entire study population. Mean cumulative duration of catheter
in situ is deﬁned as the cumulative catheter-days divided by to-
tal patients for entire study population.
Complications are deﬁned as any condition altering catheter
function that requires additional treatment.
Technical success was achieved in 22 procedures.
Technical failure occurred in 3 procedures. In 2 of them,
IVC insertion of the catheter tip failed. In remaining patient,
the catheter & the peel apart introducer were not matching
so technical failure occurred.Fig. 4 Intra-catheThe outcome of the THVA was various. Functionality
success was achieved in 20 patients (2 males & 18 females).
Functionality failure occurred in 3 patients (1 male & 2
females).
The trans-hepatic catheters stayed in place between 90 and
300 days (Table 4).
3 female patients died after duration ranged between 14 and
210 days. The causes of death were stroke & septicemic shock.
2 patients were lost of our follow up & they were considered
dead (Table 5) .
In 1 patient, bacteremia was diagnosed & treated with
proper antibiotic for proper time.
6. Complications
Complications occurred in 14 patients. Minor complications
occurred 11 times. Major complications occurred in 9 of the
patients, which coincided with 2 of the 11 minor
complications.ter thrombosis.
Table 6 Complications in terms of number and percentage.
Complications Number % Procedure
Hemorrhage 1 4
Air embolus 0 0
Contrast reaction 1 4
Major Tip infection 3 13
Dislodgement 4 17.3
Intra-vein thrombosis 0 0
Intra-cath thrombosis 3 13
Exit site infection 6 26
Minor Leakage 2 8.7
Intra-catheter air bubble 3 13
Reaction to cath material 0 0
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as decreased blood pressure, increased pulse count & ascites
with abdominal pain. Contrast reaction occurred 1 time and
manifested as shortness of breath, cold sensation & shivering.
But it did not lead to aborting
Intracatheter thrombosis occurred in 3 patients & catheters
were removed & a proper treatment was achieved with another
catheter insertion in 1 of them (Fig. 4).
Right hypochondrial pain after catheter insertion devel-
oped in 7 procedures in all of which analgesic was advised.
Pain was adequately managed by 10 mg of Paracetamol (Pan-
adol Extra, GlaxoSmithKline, USA) with no further conse-
quences in all patients.
However, the most common complication encountered was
exit site infection like cutaneous erythema, induration and
sometimes wound discharge, and it was treated by topical anti-
biotic application and sterile pads without the need to ex-
change the catheters (Fig. 5).
Also catheter dislodgement was encountered in 4 patients
(17.3%) and was attributed to respiratory motion of the chest
and abdomen.
The different complications in terms of number of patients
and their percentages are demonstrated in Table 6.
7. Discussion
Central venous stenosis and occlusion is a signiﬁcant problem
in the dialysis access population. In a large study of more than
50,000 patients with central venous catheters from theFig. 6 Catheter kinkingStrategic HealthCare Programs National Database (USA),
thrombotic occlusions caused 28% of catheter dysfunction,
the most commonly encountered complication. In these pa-
tients, 51% of the thrombi developed as a late complication
(30 days after placement) (8).
In patients with multiple failed peripheral venous access
sites for hemodialysis, unconventional venous access is an
effective means of prolonging vascular access (9). The transhe-
patic approach to hemodialysis is an optional means of vascu-
lar access for many dialysis patients who otherwise may no
longer have a suitable mode of dialysis access because of ﬁstula
failure or multiple central venous occlusions.
When comparing other unconventional vascular hemodial-
ysis access routes, such as the translumbar route, the transhe-
patic route presents in our experience less likely risk of damage
and bleeding from surrounding structures than the translum-
bar route. If complications occur, these can be easily con-
trolled if necessary by embolization of the liver parenchyma
tract. Also, the transhepatic access is often easier, especially
in obese patients. This approach can be successfully performed
even when the lower portion of the IVC is totally occluded
(10). Revision is easier than the translumbar route, in which
ﬁbrosis forms along the retroperitoneal tract, sometimes mak-
ing revision technically difﬁcult.
Three previous studies retrospectively analyzed patients
undergoing this method of catheter placement. In 2004, Smith
et al. reviewed the safety and functionality of transhepatic dial-
ysis catheters in 16 patients (1). These 16 patients had 21 sep-
arate transhepatic catheters placed. In 2003, Stavropoulos
et al. examined 12 patients with a total of 32 placed transhe-
patic catheters (11).
Our study examined 23 patients with a total of 25 placed
catheters. The depth of this number of catheters allows greater
retrospective analysis of the functionality and complications of
these catheters to determine viability better in the short-term
and long-term, which can have an impact on standard of care
in patients with limited venous access options.
Dialysis Outcomes Quality Initiatives (DOQI) states that
the intended use of tunneled central venous catheters is primar-
ily for temporary venous access, but these catheters can be
used on a long-term, permanent basis in patients who have ex-
hausted other options (i.e., AV ﬁstulas, grafts). DOQI pro-
poses a limitation of less than 10% of patients using this
method of access to reduce morbidity (3). Although placement
of transhepatic catheters has historically been indicated forin subcutaneous tissue.
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nous access site, the transhepatic method is evolving into a
long-term access site (12). It is challenging to maintain: One-
third of patients report premature dislodgment of catheters.
Smith et al. acknowledged having more difﬁculty maintaining
transhepatic access than traditional upper body access (1)Of
the two reports in the literature, Stavropoulos et al. did not
note any successful transitions to alternative, ﬁnal access sites,
whereas Smith et al. maintained ﬁve patients on the transhe-
patic route while awaiting maturation of alternative sites:
Three transitioned to AV grafts, and two transitioned to sub-
cutaneous ports in the ﬁnal access site (11,1).
In the present study, transhepatic venous catheters were
tested as the last route for dialysis, as there was no other op-
tion to fulﬁll dialysis. Although the intended temporary use
of transhepatic catheters is ideal with regard to complications
and patency rates, these catheters could be successfully main-
tained long-term. One major aspect of using the transhepatic
approach is the unpredicted long-term course. Although the
consensus opinion holds that this approach can be beneﬁcial
in the short-term, the evidence on possible long-term beneﬁts
was lacking (5). Smith et al. concluded that there was a prob-
lem in long-term functionality of catheters placed in this fash-
ion: The location proved much more difﬁcult to maintain, and
there were higher rates of bleeding complications compared
with traditional upper body access locations (1). Considerably
higher complication rates were noted compared with jugular
access in a similar patient population. Stavropoulos et al.
viewed transhepatic catheters as ideal in the short-term while
awaiting maturation of ﬁstulas or grafts, but these authors
noted that when all access sites have been exhausted, these
could prove an effective method to continue dialysis (11).
According to our outcomes, short-term (30 days) mainte-
nance of initial catheters was achieved by 86.3% of patients.
Additionally, long-term function seems to be attainable. The
incidence of catheter exchange, in some respects, seems to
overshadow the beneﬁts of the transhepatic approach. Smith
et al. found that the most common cause of catheter exchange
in their patients was device failure, a parallel outcome with our
study. In their patients, the most frequent cause of device fail-
ure was catheter thrombosis; also we found catheter thrombosis
with resulting poor function as the most frequent cause.
The short distance between the right atrium, IVC, and he-
patic vein has been shown to contribute to catheter migration
(12,13). Several studies have also indicated that respiratory
chest motion, such as coughing, and abdominal distention
seem to have a negative impact on catheter stability and pre-
dispose catheters to migration and displacement (1,14,15).
Stavropoulos et al. stated that by entering the IVC via the he-
patic vein, rather than directly entering the IVC, the chances of
migration should decrease considerably because of the greater
intravascular tract afforded by the former (11).
Finally, although not found in the literature, given the up-
right nature of the patient, the continuous force of gravity on
the tubing lying outside the abdominal cavity can factor into
the increased risk of migration. The precarious external loca-
tion of these catheters seems to predispose patients to in-
creased chances for displacement and manipulation of the
catheter. Although cuffed catheters were used, if the catheter
or cuff should be exposed to any considerable force, there is
increased risk of the cuff becoming dislodged with subsequent
catheter migration. Additionally, formation of a ﬁbrin sheathand kinking in subcutaneous tissue were noted failures of the
catheters placed in this fashion (1,11,12).
Regarding kinking, the catheter tip and lumen within the
tunneled tract seem to migrate in a retrograde fashion while
the cuff maintains its ﬁxed position; this causes the typical
‘‘Z’’ conﬁguration within the body wall and subsequently re-
duces ﬂow and leads to device failure (Fig. 6).
The literature suggests that the small size of the hepatic
vein, when examined in comparison with the jugular veins
and IVC, contributes to the forementioned complications (11).
Hepatic tract embolization after elective removal of cathe-
ters is a subject that has not achieved consensus on an appro-
priate course of action. Stavropoulos et al. performed tract
embolization with Gel foam pledges. Smith et al. did not rou-
tinely perform embolization in their patients after elective re-
moval of transhepatic catheters and did not note any
increased rate of bleeding complications.
Similarly, none of our patients underwent tract emboliza-
tion on removal of catheters, but we encountered associated
bleeding complications in one patient.
Stavropoulos et al. placed more catheters than were placed
in our study, but our infection and catheter-related sepsis rate
was less than their ﬁndings (Catheter tip infection 0.13/100
catheter-days; in our study). Their study found an infection
rate of 0.22/100 catheter-days, which necessitated catheter re-
moval in all patients because the catheter was presumed to
be the nidus of infection.
Their study found signiﬁcant thrombosis of transhepatic
catheters: 2.40/100 catheter-days. Our catheter thrombosis rate
was 0.13/100 catheter-days, which is even parallel to catheter-
related sepsis. This ﬁnding could be attributed to consistent use
of heparin after each dialysis session and at the time of place-
ment and exchanges to reduce the risk of developing thrombi.
Our catheter patency rates had an extensive impact on our
concluded long-term functionality. Primary patency was found
to be 210 catheter-days, with one patient maintaining primary
patency for 335 catheter-days. These rates are considerably
higher than the rates previously seen in conducted studies
and are less consistent with primary patency rates seen with
translumbar catheters at 250 catheter-days (1,11,16).
In current medical practice, the translumbar approach to
hemodialysis access is competing with the transhepatic ap-
proach as the next viable step in patients requiring long term
hemodialysis after loss of peripheral venous access (17,18).
Similar to the transhepatic route, puncture of the IVC through
a subcutaneous tract at the level of L2-3 below the renal veins
is completed to gain central venous access. The literature is
limited regarding the translumbar approach for hemodialysis.
With radiologists experienced in placement of these catheters,
however, technical success can be achieved (12,16,19).
The most common complications encountered with trans-
lumbar hemodialysis catheters are spontaneous migration
and dislodgment and bleeding (16,20,21). Catheter migration
is noted to be most common in obese patients, especially when
excess adipose tissue is concentrated in the truncal area
(20,21). In some institutions, patient obesity is a relative con-
traindication for placement of these catheters because the
migration out of the IVC can lead directly to retroperitoneal
hemorrhage (16,20).
Bleeding, in the form of retroperitoneal hemorrhage, has
been noted as a common occurrence in several studies accord-
ing to Biswal et al. (21). Other complications include catheter
438 M. El Gharib et al.kinking, catheter tip migration into veins other than IVC, and
non-occlusive and occlusive thrombosis, although these are
not as common as other access sites (22).
Stavropoulos et al. came to the conclusion, based on their
own experiences, that transhepatic catheter placement should
not be attempted until all alternative sites have been ex-
hausted, including the translumbar approach. The few times
that the transhepatic route was used before the translumbar
route were speciﬁcally due to interventional radiologist prefer-
ence or patient body habitus (11). Bergey et al. believed that
the transhepatic route is the preferred method with regard to
catheter removal because post-procedural bleeding can be con-
trolled more effectively with the transhepatic route via tract
embolization (22).
At our study, the transhepatic route is preferred over the
translumbar route. The transhepatic access is possible even
when the IVC is occluded. In addition, we have found the tran-
shepatic route is associated with less risk of bleeding from sur-
rounding structures. In our patient population, where
increased abdominal circumference can be a limiting factor,
the transhepatic approach is an easier option for gaining ac-
cess. Finally, if revisions are necessary, the transhepatic ap-
proach is much preferred because the translumbar approach
can be associated with ﬁbrosis along the retroperitoneal tract,
which can make revisions difﬁcult. For these reasons, in addi-
tion to the results presented in this research, we favor the tran-
shepatic approach over the translumbar approach.
There were some limitations to our study. It is a retrospec-
tive study with a relatively small subset of patients. In addition,
there was no direct comparison with other nontraditional cen-
tral venous access sites in this study. Long-term follow-up on 4
patients was limited because these patients went out of reach.
Despite these limitations, with the number of catheters placed,
especially given the relatively small number of patients in the
study population, our study suggests transhepatic catheters
have a future as a viable option for long-term hemodialysis in
situations where few resorts are available.
In contrast to previously mentioned studies that acknowl-
edge transhepatic catheters beneﬁt in short-term situations &
cite high complication rates and low patency rates as reasons
to forego their use in the long-term setting, we have shown
the complication rate to be lower than previously reported
with patency rates comparable to rates seen with the translum-
bar approach.
8. Conclusion
Several conclusions can be drawn from our study. Based on
our ﬁndings, transhepatic hemodialysis catheters have proven
to achieve good long-term functionality. A high level of main-
tenance is required to preserve patency, although this ap-
proach provides remarkably durable access for patients who
have otherwise exhausted access options.
Finally, transhepatic hemodialysis catheters offer a viable
option to patients with limited options; however, there are
maintenance issues and complications.Conﬂict of interest
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